Kathmere Capital Management LLC Has $795,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Kathmere Capital Management LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 3,049 shares of the medical research company’s stock after selling 62 shares during the quarter. Kathmere Capital Management LLC’s holdings in Amgen were worth $795,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. SS&H Financial Advisors Inc. boosted its stake in Amgen by 8.4% during the 4th quarter. SS&H Financial Advisors Inc. now owns 12,828 shares of the medical research company’s stock worth $3,344,000 after acquiring an additional 998 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its holdings in Amgen by 4.7% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 4,538 shares of the medical research company’s stock worth $1,183,000 after purchasing an additional 204 shares during the period. Community Trust & Investment Co. boosted its position in shares of Amgen by 3.4% during the fourth quarter. Community Trust & Investment Co. now owns 11,446 shares of the medical research company’s stock worth $2,983,000 after purchasing an additional 374 shares in the last quarter. Peoples Financial Services CORP. grew its holdings in shares of Amgen by 1.0% in the 4th quarter. Peoples Financial Services CORP. now owns 4,850 shares of the medical research company’s stock valued at $1,264,000 after buying an additional 50 shares during the period. Finally, R.H. Investment Group LLC bought a new stake in shares of Amgen in the 4th quarter valued at $3,784,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMGN has been the topic of several recent analyst reports. Piper Sandler reduced their target price on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. Deutsche Bank Aktiengesellschaft decreased their price objective on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Jefferies Financial Group restated a “buy” rating and set a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. William Blair reiterated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Finally, Robert W. Baird restated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a report on Wednesday, September 25th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Stock Up 0.7 %

Amgen stock opened at $268.94 on Thursday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The company’s 50-day moving average is $277.12 and its 200-day moving average is $308.03. The firm has a market capitalization of $144.56 billion, a PE ratio of 34.44, a P/E/G ratio of 2.91 and a beta of 0.56. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business’s revenue was up 23.2% on a year-over-year basis. During the same period last year, the firm posted $4.96 earnings per share. Sell-side analysts anticipate that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.54%. Amgen’s dividend payout ratio is presently 121.90%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.